No Data
No Data
Guotou Securities: The investment and financing environment for Innovative Drugs is rebounding, CXO Orders and performance improvements are expected.
Global investment and financing in Innovative Drugs continues to improve, and a recovery in R&D demand is anticipated; new Orders are recovering in a timely manner, and there is optimism for improved CXO performance in 2025.
Hong Kong stocks fluctuate | Asymchem Laboratories (06821) rose over 4% in the last trading session. First-quarter net profit increased over 15%, and emerging Business achieved revenue growth of over 80% year-on-year.
Asymchem Laboratories (06821) rose over 4% in the late trading session, up 4.34% as of this writing, priced at 52.85 Hong Kong dollars, with a transaction volume of 75.7835 million Hong Kong dollars.
The Trump administration plans to impose tariffs on imported Pharmaceuticals, and the U.S. Pharmaceutical Industry warns that it may increase drug costs.
A report commissioned by a trade organization in the USA Pharmaceutical Industry indicates that if the USA imposes a 25% tariff on imported Pharmaceuticals, it could increase the annual Pharmaceutical costs in the USA by nearly 51 billion dollars and raise drug prices by up to 12.9%.
Nomura Adjusts Asymchem Laboratories (Tianjin)'s Price Target to 77.96 Yuan From 107.91 Yuan, Keeps at Buy
Asymchem Laboratories (06821) granted 4.896 million shares of restricted stocks.
Asymchem Laboratories (06821) announced that the Board of Directors believes the company's "2025 Restricted Stock Incentive Plan (Draft)...
Accelerating recovery? In March, domestic Innovative Drugs investment and financing increased by about 50% year-on-year, and the Hong Kong Stock pharmaceutical Sector collectively surged.
① In March, domestic investment and financing for Innovative Drugs increased by approximately fifty percent year-on-year, how significant is the Bullish impact? ② The Hong Kong stock market's pharmaceutical Sector rose collectively, which stocks are attracting market attention?